Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228)

Journal of Cellular Physiology

Volumn 203, Issue 2, 2005, Pages 387-397

  Sutheesophon, Krittaya ^a   Nishimura, Noriko ^a   Kobayashi, Yukiko ^a   Furukawa, Yutaka ^a   Kawano, Mikihiko ^a   Itoh, Kouichi ^a   Kano, Yasuhiko ^b   Ishii, Hideshi ^a   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 7; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ACETYLATION; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES; APOPTOSIS; AUTOCRINE COMMUNICATION; CASPASES; CELL TRANSFORMATION, NEOPLASTIC; DEPSIPEPTIDES; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HISTONES; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 16344380408     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20235     Document Type: Article

References (48)

1. Agalioti T, Chen G, Thanos D. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381-392.
2. Amin HM, Saeed S, Alkan S. 2001. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 115:287-297.
3. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC. 2003. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylation in chronic lymphocytic leukemia cells concurrent with activation of caspase-8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652-658.
4. Baker SJ, Reddy EP. 1998. Modulation of life and death by the TNF receptor superfamily. Oncogene 17:3261-3270.
5. Baker PK, Pettitt AR, Slupsky JR, Chen HJ, Glenn MA, Zuzel M, Cawley JC. 2002. Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion. Blood 100:647-653.
6. Barnhart BC, Peter ME. 2003. The TNF receptor 1: A split personality complex. Cell 114:148-150.
7. Barthel R, Tsytsykova AV, Barczak AK, Tsai EY, Dascher CC, Brenner MB, Goldfeld AE. 2003. Regulation of tumor necrosis factor alpha gene expression by mycobacteria involves the assembly of a unique enhanceosome dependent on the coactivator proteins CBP/p300. Mol Cell Biol 23:526-533.
8. Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, Csordas A, Kofler R. 1999. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J 13:1991-2001.
9. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. 1999. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269-290.
10. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. 1999. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401-1408.
11. Darzynkiewicz Z, Carter SP, Old LJ. 1987. Effect of recombinant tumor necrosis factor on HL-60 cells: Cell-cycle specificity and synergism with actinomycin D. J Cell Physiol 130:328-335.
12. Waf1/Cip1 and cyclin D1 is increased in butyrate-resistant HeLa cells. J Biol Chem 276:37815-37820.
13. Falvo JV, Uglialoro AM, Brinkman BMN, Merika M, Parekh BS, Tsai EY, King HC, Morielli AD, Peralta EG, Maniatis T, Thanos D, Goldfeld AE. 2000. Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter. Mol Cell Biol 20:2239-2247.
14. Fuchs P, Strehl S, Dworzak M, Himmler A, Ambros PF. 1992. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics 13:219-224.
15. Furukawa Y, DeCaprio JA, Freedman AS, Kanakura Y, Nakamura M, Ernst TJ, Livingston DM, Griffin JD. 1990. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci USA 87:2770-2774.
16. Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S, Yamada H, Matsuda M, Kano Y, Nakamura M. 2002. Apaf-1 is a mediator of E2F-1-induced apoptosis. J Biol Chem 277:39760-39768.
17. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. 2003. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
18. Gore SD, Weng L-J, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. 2002. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963-970.
19. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. 2003. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579-12589.
20. Hong S-H, David G, Wong C-W, Dejean A, Privalsky ML. 1997. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:9028-9033.
21. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293:1074-1080.
22. Johnstone RW, Licht JD. 2003. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4:13-18.
23. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. 2001. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11:162-166.
24. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang J-E, Lee S-W, Moon E-J, Kim H-S, Lee S-K, Chung HY, Kim CW. 2001. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Med 7:437-443.
25. Kumakura S, Ishikura H, Maniwa Y, Munemasa S, Tsumura H, Masuda J, Kobayashi S. 2003. Activation of protein kinase C enhances TNF-alpha-induced differentiation by preventing apoptosis via rapid up-regulation of c-Myc protein expression in HL-60 cells. Leuk Lymphoma 44:497-503.
26. Kwon SH, Ahn SH, Kim YK, Bae G-U, Yoon JW, Hong S, Lee HY, Lee Y-W, Lee H-W, Han JW. 2002. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277:2073-2080.
27. Lin RJ, Nagy L, Inoue S, Shao W, Miller JWH, Evans RM. 1998. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 391:811-814.
28. Maeda T, Towatari M, Kosugi H, Saito H. 2000. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96:3847-3856.
29. Mariadason JM, Corner GA, Augenlicht LH. 2000. Genetic reprogramming in pathways of colonic cell mutation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60:4561-4572.
30. Melnick A, Licht JD. 2002. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 9:322-332.
31. Minucci S, Nervi C, Coco FL, Pelicci PG. 2001. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20:3110-3115.
32. Murata M, Towatari M, Kosugi H, Tanimoto M, Ueda R, Saito H, Naoe T. 2000. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn J Cancer Res 91:1154-1160.
33. Nakayama J-I, Rice JC, Strahl BD, Allis CD, Grewal SIS. 2001. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292:110-113.
34. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE. 2001. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 98:2865-2868.
35. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. 2000. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11:2069-2083.
36. WAF1 expression and gene-associated histone deacetylation. Proc Natl Acad Sci USA 97:10014-10019.
37. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. 2001. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characetrized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838.
38. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE. 2000. P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817-825.
39. Sandor V, Bakke S, Robery RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. 2002. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728.
40. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet 31:141-149.
41. Taddei A, Maison C, Roche D, Almouzni G. 2001. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3:114-120.
42. Takashiba S, Shapira L, Amar S, Van Dyke TE. 1993. Cloning and characterization of human TNFα promoter region. Gene 131:307-308.
43. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. 1994. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. J Antibiotic 47:315-323.
44. Wajant H, Johannes F-J, Haas E, Siemienski K, Schwenzer R, Schubert G, Weiss T, Grell M, Scheurich P. 1998. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr Biol 8:113-116.
45. Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF. 1985. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149-154.
46. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. 2001. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98: 13884-13888.
47. Warrell RPJ, He LZ, Richon V, Calleja E, Pandolfi PP. 1998. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621-1625.
48. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. 2002. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2:485-495.